Recently diagnosed with HIV? Click here



Maraviroc targets the CCR5 co-receptor used by HIV to gain entry to human cells. Drugs in this class are called CCR5 antagonists, attachment inhibitors or entry inhibitors. They work by attaching themselves to a protein on the surface of CD4 cells called CCR5, blocking the virusA small infective organism which is incapable of reproducing outside a host cell. from entering the cell. Drugs from this class are particularly useful for treatment-experienced people who have developed resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. to other drugs and classes.

CCR5 antagonists can be effective against HIV because they prevent HIV from entering immune system cells (most anti-HIV drugs disrupt the virus' action inside the cells). There is some concern however that the use of CCR5 antagonists could cause HIV to evolve to use another co-receptor, CXCR4, for which no blocking drugs are available. People with lower CD4 cells often have some CXCR4-tropic virus, and this may be associated with more aggressive HIV illness compared with the more common CCR5-tropic virus, so this change could have negative impacts.

To avoid this happening, tests must first be performed to determine the type of virus you have, and people with CXCR4-tropic virus, and those with dual tropism (a combination of both types of virus) are excluded from using this drug.

Generic name: maraviroc (MVC)
Brand name:Celsentri
Also known as:UK-427,857 (former code name)
Selzentry® (US brand name)
Drug class:CCR5 antagonist
Availability in Australia:
  • Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers since 2010.
  • This drug may be available through clinical trials in Australia.
  • You may be able to import this drug from overseas for your personal use.
Presentation:150mg tablet; 300mg tablet.

Like most anti-HIV drugs, maraviroc must be taken in combination with other drugs to be completely effective. Your doctor will advise you on the right combination of drugs to suit your circumstances.


The usual adult dose is one 300mg tablet taken twice a day.

Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.

Side effects

All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.

  • Common side effects may include rash, abdominal pain, fever, cough, upper respiratory tract infections, musculoskeletal symptoms, dizziness..
  • Less common side effects may include liver toxicity.
  • It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.

Interactions with other drugs

Numerous other drugs can affect the levels of maraviroc in the bloodstream, including some anticonvulsant drugs, drugs used to treat infections like TB or MAC, anti-HIV treatments and other drugs which may or may not be related to you HIV treatment. Always tell your doctor about all drugs you are taking (including over-the-counter medicines and herbal treatments).
pfccelst.pdf28.04 KBpfccelst.pdfPDF
5_ Celsentri CMI.pdf434.38 KB5_ Celsentri CMI.pdfPDF

The entry inhibitor

Positive Living article • Jae Condon • 30 August 2013

HIV is unable to replicate by itself, so needs a host cell to be able to reproduce and make more HIV. That host cell is the human CD4 cell, also called a T-cell. To begin this replication cycle HIV must first enter the CD4 cell, and this entry process involves a number of stages. read more »

Report from Rome - 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention

Story • • 28 July 2011

The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention was held in Rome last week from 17-20 July. This meeting is held every two years and alternates with the much larger World AIDS Conferences also organised by the International AIDS Society (IAS). read more »

Snippets from ASHM

Positive Living article • Adrian Ogier • 2 December 2010
Treating HIV

The Australasian HIV/AIDS Conference was held in Sydney in October. Here are some of the treatment highlights: read more »

AIDS 2008: Is the HIV drug pipeline drying up?

Positive Living article • David Menadue • 24 September 2008

The International AIDS Conference heard promising reports about the newer HIV treatments designed to help treat people with advanced and drug-resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant. HIV, all of which are now available in Australia. read more »

IAS 2007: Promising signs

Positive Living article • Paul Kidd • 15 October 2007

A major HIV/AIDS medical conference in Sydney has generated lots of news on the treatments front, reports Paul Kidd. read more »

CROI 2007: A great leap forward

Positive Living article • Paul Kidd • 22 March 2007

A major scientific conference on HIV has wound up with promising news on treatments which could signal a significant improvement in HIV treatment for the first time in some years. read more »

ASHM 2006: Strategies for coping with multiple drug resistance

Positive Living article • Paul Kidd • 21 December 2006
Treating HIV

Finding effective treatment options for people who have taken many treatments and have multiple resistanceHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistantHIV which has mutated and is less susceptible to the effects of one or more anti-HIV drugs is said to be resistant.. mutations continues to be a significant challenge for HIV clinicians, and their patients. read more »

Time to deliver

Positive Living article • John Daye • 5 October 2006

The 16th International AIDS Conference highlighted numerous important and promising developments in HIV treatments. JOHN DAYE reports. read more »

Much more than a junket

Positive Living article • Paul Kidd • 13 October 2005

A report from the 3rd IAS Conference on HIV Pathogenesis and Treatment, held in Rio de Janiero in July. read more »

The bleeding edge

Positive Living article • John Daye • 19 May 2005

The annual Retrovirus Conference is a key event on the HIV scientific calendar, and regularly highlights the most exciting ‘bleeding edge’ developments from the world of HIV science. read more »

The table below shows all the clinical trials in the database with the keyword maraviroc.

Syndicate content
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Treatments database entry was first published on 3 June 2009 — more than four years ago.

While the content of this treatments database entry was checked for accuracy at the time of publication, NAPWHA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWHA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.